Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:34:06.862Z.
Calculation as of: 2026-10-06T16:34:06.862Z.
Quote observation: 2026-10-06T16:27:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$104.68M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.52M
Price/FCF Ratio
3.69
TTM Avg
4.64
3Y Avg
13.17
5Y Avg
35.61
Market Cap
$107.36M
Price/FCF Ratio
N/A
TTM Avg
23.61
3Y Avg
13.61
5Y Avg
10.78
Market Cap
$103.94M
Price/FCF Ratio
N/A
TTM Avg
17.97
3Y Avg
17.97
5Y Avg
17.97
Market Cap
$102.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.65M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.50M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $104.68M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.52M | 3.69 | 4.64 | 13.17 | 35.61 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.36M | N/A | 23.61 | 13.61 | 10.78 |
| Anixa Biosciences, Inc. (ANIX)vs › | $103.94M | N/A | 17.97 | 17.97 | 17.97 |
| The Joint Corp. (JYNT)vs › | $102.85M | 24.32 | 107.29 | 57.88 | 61.33 |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.46M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.65M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $108.02M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.50M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.30M | N/A | 8.08 | 8.08 | 8.08 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
